SPRB logo

SPRUCE BIOSCIENCES INC

SPRBNASDAQ
🏆 #3834 by market capEarnings Nov 9 · PostUS Equity
$47.16▲ $1.87 (+4.13%)
Pre-market · at close
🔔
Track SPRB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.1%
7d▲ 3.1%
14d▲ 15.4%
30d▲ 0.5%
ytd▼ 44.1%
1y▼ 58.1%
🏦Market Cap
$135M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
26.7x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$45.73 – $47.16
52-Week Range
$38.06 – $138.45
Volume (shares)
2,273
Avg Volume (shares)
—
Shares Outstanding
2.9M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
26.7x
EPS (TTM)
$-38.31
Dividend Yield
—
Dilution (1yr)
+42.9%
SPRB logo

SPRUCE BIOSCIENCES INC

SPRB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$37M▼ −35.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −40.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
767K▲ +42.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$48M▲ +$12M YoY
StockOtter · stockotter.space

About SPRUCE BIOSCIENCES INC

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
15 analysts
Strong Buy5
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.